Osmotica pharmaceuticals plc (OSMT)
CashFlow / Yearly
Dec'19Dec'18Dec'17
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-270,901

-109,681

-41,141

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

57,015

81,573

46,450

Share compensation

4,932

1,965

-

Impairment of intangibles and fixed assets

-

-

72,986

Impairment of goodwill

0

86,318

0

Deferred income tax benefit

-26,794

-15,513

-

Impairment of intangibles

283,747

17,903

-

Deferred income tax benefit

-

-

-48,506

Loss on sale of fixed and leased assets

-173

-93

-

Bad debt provision

-164

-1,771

832

Expensed IPR&D

-

-

16,372

Change in fair value of contingent consideration

-

-

182

Payment for contingent consideration

-

-

1,991

Payment of in-kind interest

-

-

9,321

Amortization of deferred financing and loan origination fees

1,337

1,652

-

Non-cash interest expense and amortization of deferred financing and loan origination fees

-

-

7,506

Write off of deferred financing fees in connection with prepayment

-

876

4,981

Change in operating assets and liabilities:
Trade accounts receivable, net

-12,674

17,041

-5,268

Inventories, net

-3,078

7,436

-2,892

Prepaid expenses and other current assets

-9,177

-4,549

14,569

Other non‑current assets

-

-

-1,512

Trade accounts payable

-16,375

-11,326

588

Accrued and other current liabilities

-24,332

5,397

13,794

Net cash used in operating activities

33,567

37,558

57,837

CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of fixed and leased assets

17

10

-

Payments on disposal of leased assets

74

-

-

Payment for asset acquisition

-

-

12,500

Purchase of property, plant and equipment

3,963

4,144

6,895

Net cash used in investing activities

-4,020

-4,134

-19,395

CASH FLOWS FROM FINANCING ACTIVITIES:
Payments to affiliates

-

2

-

Payments on finance lease obligations, ASC842

130

-

-

Contributions from Partners

-

-

128

Payments on finance lease obligations, ASC840

-

112

113

Proceeds from public offering, net of issuance costs

-

58,084

-

Debt repayment

-

56,140

338,756

Repurchases of ordinary shares

2,787

-

-

Proceeds from issuances of debt

-

-

327,500

Debt financing costs

-

-

3,563

Proceeds from insurance financing loan

1,314

2,745

-

Repayment of insurance financing loan

3,088

971

-

Payment for contingent consideration

-

-

8,508

Net cash provided by (used in) financing activities

-4,691

3,604

-23,314

Net change in cash and cash equivalents

24,856

37,028

15,127

Effect on cash of changes in exchange rate

175

-938

57

Supplemental disclosure of cash and non‑cash transactions:
Cash paid for interest

15,181

19,619

25,272

Cash paid for taxes

1,290

2,638

17,592